Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for moderate-to-severe plaque psoriasis. The double-blind, placebo-controlled ...

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, and Vicore Pharma, a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 ...

Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel ...

Preclinical Data Highlight TP-317’s Anti-Inflammatory, Epithelial Barrier-Protective Effects ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...

NKGen Biotech (NKGN) announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator for its Phase 2a clinical ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.